Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01836471 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients

A Phase 2 study of Asthma, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
345
Enrollment target
20
Study locations

NCT01836471 is a Phase 2 study of Asthma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 345 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01836471, a Phase 2 study of Asthma, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
345 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study was to assess the clinical effect of QAW039 in non-atopic asthmatics taking low dose Inhaled Corticosteroid (ICS) as background therapy.

Conditions Studied

Asthma

Interventions

  • DRUG QAW039
  • DRUG Placebo QAW039
  • DRUG Fluticasone 250 mcg
  • DRUG Fluticasone 100 mcg

Study Locations (20)

California

  • Novartis Investigative Site - Encinitas
  • Novartis Investigative Site - Huntington Beach
  • Novartis Investigative Site - Los Angeles
  • Novartis Investigative Site - Los Angeles
  • Novartis Investigative Site - Mission Viejo
  • Novartis Investigative Site - Orange
  • Novartis Investigative Site - Palmdale
  • Novartis Investigative Site - Riverside
  • Novartis Investigative Site - Rolling Hills Estates
  • Novartis Investigative Site - San Diego
  • Novartis Investigative Site - San Jose
  • Novartis Investigative Site - Stockton

Colorado

  • Novartis Investigative Site - Colorado Springs
  • Novartis Investigative Site - Denver
  • Novartis Investigative Site - Denver

Florida

  • Novartis Investigative Site - Sarasota

Kentucky

  • Novartis Investigative Site - Owensboro

Massachusetts

  • Novartis Investigative Site - North Dartmouth

Minnesota

  • Novartis Investigative Site - Minneapolis

Missouri

  • Novartis Investigative Site - St Louis

Trial Details

FieldValue
Enrollment Target 345 participants
Start Date 2013-05
Est. Completion 2016-02
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01836471

The ClinicalTrials.gov registry entry for NCT01836471 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (78% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 4 interventions - of which QAW039 is the first listed.

NCT01836471 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT01836471 about?

NCT01836471 is a clinical study titled "A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients". The purpose of the study was to assess the clinical effect of QAW039 in non-atopic asthmatics taking low dose Inhaled Corticosteroid (ICS) as background therapy.

What is the current status of trial NCT01836471?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 345 participants. The study started on 2013-05. Estimated completion is 2016-02.

What conditions does trial NCT01836471 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT01836471?

The interventions under investigation include: QAW039 (DRUG), Placebo QAW039 (DRUG), Fluticasone 250 mcg (DRUG), Fluticasone 100 mcg (DRUG).

Who is sponsoring clinical trial NCT01836471?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01836471 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.